Introduction |
Welcome to our invitation for contributions to and registrations for the Joint Meeting between DMDG and the Swedish Academy of Pharmaceutical Sciences. We have a great programme, which caters for the breadth of membership from both organisations. We hope that you are inspired to both join us and contribute a poster at this year’s meeting, as well as contributing to the great discussion that the topics chosen will generate.
We are pleased to announce that, after a number of years absence, our highly popular and entertaining debate returns this year. Steve Hood will be presiding as 'ringmaster' as Kevin Brady (UCB) and Ben Krippendorf (Roche) go head-to-head with Dennis Smith (DMDG Fellow) and Barry Jones (AstraZeneca) to debate whether "Lipinski Rules are no longer relevant – Future drugs will need to be >5 kDa if they are to become 'profitable' medicines." Magnus, is a Professor at Karolinska Institute. He has authored or co-authored more than 420 original papers and is ranked the 3rd most impactful researcher in the field of drug metabolism (cytochrome.net) and one of the world's most cited authors within the category Pharmacology (http://isihighlycited.com/). His research is currently focused on genetic factors of importance for interindividual differences in drug response, adverse drug reactions and on novel 3D hepatic in vitro systems by which liver function, mechanisms of drug mediated enzyme induction and drug hepatotoxicity can be studied under healthy and various disease conditions, e.g. steatosis, hepatitis and fibrosis.
Peptide ADME Discussion Group - 1st Workshop
Accommodation You are advised to book a hotel as soon as you have registered to ensure your accommodation.
|
In partnership with: Sponsored by:
|